The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Byung Gyu KimNeung Hwa ParkSeung Bum LeeSoyoung JeonJae Ho ParkSeok Won JungIn Du JeongSung-Jo BangJung Woo ShinPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
The incidence rate of HCC may not change significantly before and after 5 years of ETV therapy in Korean CHB patients. The risk of HCC in Asian CHB patients may remain in the long-term.